Maxim Group restated their buy rating on shares of Sientra (NASDAQ:SIEN) in a research report report published on Monday. The brokerage currently has a $20.00 price target on the medical instruments supplier’s stock.

Other analysts have also recently issued reports about the stock. ValuEngine cut shares of Sientra from a strong-buy rating to a buy rating in a report on Thursday, January 24th. Zacks Investment Research raised shares of Sientra from a sell rating to a hold rating in a report on Wednesday, November 7th. Finally, BidaskClub cut shares of Sientra from a hold rating to a sell rating in a report on Tuesday, November 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of Buy and an average price target of $22.63.

Shares of NASDAQ:SIEN opened at $10.43 on Monday. The firm has a market cap of $293.14 million, a price-to-earnings ratio of -3.70 and a beta of -0.03. Sientra has a 1-year low of $8.79 and a 1-year high of $26.79. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.34 and a current ratio of 2.77.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Sientra by 2.8% during the fourth quarter. BlackRock Inc. now owns 1,616,583 shares of the medical instruments supplier’s stock worth $20,546,000 after acquiring an additional 43,684 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Sientra by 1.4% during the third quarter. Vanguard Group Inc. now owns 1,017,312 shares of the medical instruments supplier’s stock worth $24,293,000 after acquiring an additional 14,422 shares during the last quarter. Vanguard Group Inc grew its position in shares of Sientra by 1.4% during the third quarter. Vanguard Group Inc now owns 1,017,312 shares of the medical instruments supplier’s stock worth $24,293,000 after acquiring an additional 14,422 shares during the last quarter. Northern Trust Corp grew its position in shares of Sientra by 74.2% during the second quarter. Northern Trust Corp now owns 270,559 shares of the medical instruments supplier’s stock worth $5,278,000 after acquiring an additional 115,283 shares during the last quarter. Finally, United Services Automobile Association grew its position in shares of Sientra by 17.7% during the third quarter. United Services Automobile Association now owns 237,529 shares of the medical instruments supplier’s stock worth $5,672,000 after acquiring an additional 35,760 shares during the last quarter. Institutional investors and hedge funds own 86.62% of the company’s stock.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Featured Article: How prevalent are 12b-1 fees?

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.